tbuckley/cabot-search huggingface dataset:
Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.
Authors: Michael Lee, Martin R Jones, Laura Williamson, James Thomas Topham, Sean Addison, Hui-Li Wong, Rob Denroche, Gun Ho Jang, Joanna Karasinska, John Paul McGhie, Sharlene Gill, Howard John Lim, Stephen Yip, Jennifer J. Knox, Steven Gallinger, Janessa J. Laskin, Marco A. Marra, Steven J. M. Jones, David F Sschaeffer, Daniel John Renouf
Journal: Journal of Clinical Oncology (2019)

273 Background: Substantial progress has been made in the understanding of the genomic landscape of PDAC, but the clinical utility of these data remains uncertain. Methods: As part of the BC Cancer Personalized Oncogenomics (POG) and PanGen studies, whole genome analysis and transcriptome sequencing were performed on fresh biopsy and blood sample from 47 mPDAC patients. Genomic findings informed therapy choices including potential eligibility for the CCTG PM.1 molecular basket trial. Results: Cohort consists of 53% male, average age 57.8, 34/47 had ≥2 lines of treatment. 37/47 biopsies were from liver and 26/47 were collected pre-treatment. 8/47 (17%) patients had aberrations with strong evidence of clinical actionability. These include 2 germline BRCA2, 1 germline BRCA1, 1 somatic XRCC2 homozygous deletion with strong COSMIC signature 3, all predictive of platinum sensitivity. Patients with XRCC2 deletion and BRCA1 had over 2 years on FOLFIRINOX. Fusions affecting the NRG1 gene were identified in 3 patients, all with KRAS wildtype tumours, which may confer ERRB inhibitor sensitivity. 1/3 NRG1 fusion patients had thus far been treated with the ERBB inhibitor afatinib, with reduction of CA19-9 from &gt;120,000 to 7246 and dramatic response noted on PET CT imaging one month post treatment. One patient had mismatch repair deficiency, and a high mutational burden, suggestive of immune checkpoint inhibitor sensitivity. In total 85% (40/47) sequenced mPDAC patients had potentially actionable mutations which includes CCTG PM.1 trial eligibility: 24/47 with cell cycle dysregulation (CDK4/6 inhibitor arm), 4/47 with high homologous recombination defects (PARP inhibitor arm), 1/47 ERBB2 amplification (anti-HER2 arm), 2/47 high expression of FGFR1 (Sunitinib arm) and 1/47 with high FLT4 and IGF1R expression (Axitinib arm). Conclusions: More routine use of comprehensive genomic analysis should be considered in mPDAC given finding of high degree of actionability. Importantly, a significant proportion (17%) had findings with strong evidence of clinical impact.(NCT02155621, NCT02869802, NCT03297606)
Pathogen Inactivated Platelet Components Used without Leukofiltration, or Gamma Irradiation Show Comparable Therapeutic Efficacy and Safety to Gamma Irradiated and Non-Leukofiltered Conventional Products for the Support of HSCT Patients in Hong Kong
Authors: Joycelyn Sim Pui Yin, Rock Leung Yuk Yan, Clarence Lam Chun Kit, Chiu Tsoi Wai, Kwong Lee Cheuk, Albert Lie Kwok Wai, Norman Huang, Salvador Rico, Jin-Sying Lin, Laurence Corash, Adonis Stassinopoulos
Journal: Blood (2016)
Device for Cluster Headache
Authors: Rebecca Voelker
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nutmeg liver, fever and elevated liver enzymes in a young man
Authors: Aleksandar Gavrić, Rok Dežman, Branislava Ranković, Marija Ribnikar, Borut Štabuc
Journal: Gut (2019)

A 27-year-old man was admitted to our department because of persistent symptoms of fever, dyspnoea, dry cough, elevated C reactive protein (CRP) (258 mg/L), leucocytosis (17×109/L), peripheral eosinophilia (29%) and elevated liver enzymes (alanine aminotransferase (ALT) 518.2 U/L; aspartate aminotransferase (AST) 192.4 U/L; total bilirubin 1.6 mg/dL direct bilirubin 0.7 mg/dL; alkaline phosphatase 115.9 U/L and gamma glutamyl transferase (GGT) 119,4 U/L). His medical history was unremarkable except for surgery that he underwent 3 weeks ago for his left radius and ulna fracture. Since the surgery, he has been taking paracetamol and sodium metamizole. Empirical antibiotic therapy was initiated.

Chest X-ray revealed small left and large right pleural effusion. CT was performed due …
Inhibiting neuraminidase can make the difference
Authors: Rino Rappuoli, Giuseppe Del Giudice
Journal: The Journal of Experimental Medicine (2019)

Immunogens inducing antibodies against the stem of influenza virus hemagglutinin are promising candidates for the development of universal vaccines. In this issue of JEM, Kosik et al. (https://doi.org/10.1084/jem.20181624) report that inhibition of neuraminidase by anti-stem antibodies contributes to their broadly neutralizing activity.
Feasibility study of diet counseling (DC) with oral nutritional supplements (ONS) for advanced esophageal and gastric cancer during chemotherapy (CT) or chemoradiotherapy (CRT): First report of ONS compliance from a prospective randomized controlled clinical study (DiCON study).
Authors: Yukiko Izawa, Takashi Ichimura, Keisho Chin, Eiji Shinozaki, Daisuke Takahari, Mitsukuni Suenaga, Mariko Ogura, Takeru Wakatsuki, Hiroki Osumi, Izuma Nakayama, Shinji Mine, Naoki Hiki, Naoki Ishizuka, Kensei Yamaguchi
Journal: Journal of Clinical Oncology (2019)

17 Background: Most advanced esophageal and gastric cancer patients(pts) experience fatigue, anorexia, and may arise malnutrition and sarcopenia, for which effective treatment has not been established. Nutritional support especially protein supplementations may prevent loss of body mass related with malnutrition and sarcopenia. We therefore, conducted a prospective randomized study to explore compliance and the best available ONS intake for pts undergoing CT or CRT. Methods: Eligibility criteria included: chemo-naïve advanced gastric cancer or esophageal cancer; performance status (PS) of 0–1; pts who can eat more than as 50% as usual; age over 20 years. Pts were randomly allocated into four groups within each strata, i.e. esophageal or gastric cancer, Group A: Diet counseling (DC) only, Group B-1: DC and ONS 1 pack/day, Group B-2: DC and ONS 2 packs/day, and Group B-3: DC and ONS 3 packs/day. We use jelly type ONS which is easy to intake and include rich branched-chain amino acid. We assessed ONS compliance, the change of nutritional index (body weight, albumin, pre-albumin, and muscle mass), diet record (daily), and toxicity before CT or CRT and 14 days after administration of CT. Results: Among forty pts (11 in A, 11 in B-1,8 in B-2,10 in B-3) were enrolled from August 2017 to August 2018, median age was 64 years (range 46-81), median BMI was 20.6 (range 15-29), and 28 gastric cancer, 12 esophageal cancer. Median intake was 12 packs/2w (range 0-14), 15 packs/2w (3-28), 12 packs/2w (2-28), in B-1, B-2, and B-3 respectively. Mean compliance of ONS was 72.7%, 50.0% and 33.1%, in B-1, B-2, and B-3 respectively. There was a significant linear trend across the 3 groups (P = 0.0104). B-1 was significantly better than B-3 (P = 0.0270). There were no pts in group B-3 who could intake ONS for 14 consecutive days. Over 80% of pts in B-1 group were able to intake for 14 consecutive days. Conclusions: We found ONS 3 packs/day was clearly denied because of compliance. Choice of 1 or 2 packs/day should be determined by taking into account the total calories of foods. Clinical trial information: 000026705.
Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.
Authors: Dominik Paul Modest, Ingrid Ricard, Kathrin Heinrich, Ludwig Fischer von Weikersthal, Thomas Decker, Ursula Vehling-Kaiser, Ullrich Graeven, Arndt Stahler, Andreas Jung, Thomas Kirchner, Swantje Held, Sebastian Stintzing, Clemens Giessen-Jung, Volker Heinemann
Journal: Journal of Clinical Oncology (2019)

549 Background: XELAVIRI compared initial versus sequential irinotecan (iri) in combination with fluoropyrimidine (FP) plus bevacizumab (bev) in patients (pts) with mCRC, trial identification: NCT01249638. In the full analysis set of the study, non inferiority of time to failure of strategy (TFS) of the sequential use could not be demonstrated (primary endpoint). Methods: The secondary endpoints overall response rate (ORR), progression-free survival (PFS) as well as overall survival (OS) were evaluated in female versus male pts as well as molecular subgroups (RAS mutational status). Interaction of treatment and gender was tested by likelihood ratio tests. Results: Of 421 patients, 281/140 were male/female. In female pts, ORR was 43% in both arms, PFS was 8.9 (95% CI 6.8-11.1) versus 10.1 (95% CI 8.5-11.8) months (HR: 1.09 (95% CI 0.76-1.55), P = 0.65) in pts with initial iri versus pts without initial iri, respectively. In females, a trend for inferior OS with initial iri was seen: 21.8 (95% CI 14.8-28.8) months with initial iri versus 28.4 (95% CI 21.9-34.9) months without initial iri (HR: 1.46 (95% CI 0.95-2.24), P = 0.08). This difference was significant in the multivariate analysis (HR: 1.73 (95% CI 1.04-2.86, P = 0.034). Male pts benefitted across all analysed endpoints from initial iri: ORR was 58.3% with initial iri and 33.6% without iri (P &lt; 0.001), PFS was 10.1 (95% CI 9.2-11.0) versus 7.4 (95% CI 6.3-8.5) months (HR: 0.54 (95% CI 0.42-0.69) P &lt; 0.001) and OS 23.9 (95% CI 19.1- 28.6) versus 20.5 (95% CI 18.1-22.9) months (HR: 0.63 (95% CI 0.47-0.85), P = 0.002), with initial iri versus without initial iri, respectively. Interaction of treatment and gender was seen for ORR (P = 0.018), PFS (P = 0.002) and OS (P = 0.001). Additional data including treatment and toxicities will be presented at the meeting. Conclusions: This unplanned exploratory analysis suggests that gender might interact with efficacy of initial iri when used in the context of FP and bev. While male patients derived a significant and clinically meaningful benefit from initial use of iri, this was not observed in female patients. Clinical trial information: NCT01249638.
Abstract 18732: Sedentary Lifestyle Associated With Mortality in Patients With Heart Failure Who Monitor Weight and Symptoms
Authors: Linda G Park, Kathleen A Dracup, Mary A Whooley, Charles McCulloch, Chengshi Jin, Jill Howie-Esquivel
Journal: Circulation (2017)

Introduction: Mortality rates after the onset of symptomatic heart failure (HF) are extremely high with varying rates reported, reflecting differences in disease severity, medical therapy, and self...
The timing is right to end snakebite deaths in South Asia
Authors: Ravikar Ralph, Sanjib Kumar Sharma, Mohammad Abul Faiz, Isabela Ribeiro, Suman Rijal, François Chappuis, Ulrich Kuch
Journal: BMJ (2019)

Regional collaboration is crucial to end preventable deaths and disability from snakebites in South Asia, say Ravikar Ralph and colleagues ### Key messages Five million snakebites occur globally each year, causing between 81 000 and 138 000 deaths and nearly 400 000 amputations and other permanent disabilities.1 South Asia has the highest incidence of venomous snakebites in the world.2 Within the region, Bangladesh, India, Nepal, Pakistan, and Sri Lanka together constitute nearly 70% of global snakebite mortality.3 The World Health Organization recognised snakebite as a neglected tropical disease in 2017, giving it high priority for large scale action and research.4 A resolution passed in the World Health Assembly in May 2018 urged member states to step up efforts to tackle snakebite.56 It is important that regional mitigation efforts in South Asia reflect these objectives. In this paper, we explore the determinants of poor clinical outcomes with snakebite in South Asia and propose priority actions for governments to achieve the vision of zero deaths from snakebite. The region is a biodiversity hotspot for venomous snake species. The sociodemographic and occupational profile of the population contributes to increased risk of snake-human encounters. Snakebites are largely an agrarian occupational hazard in South Asia. Box 1 describes the medically important snake species in South Asia and demographic profile of groups commonly affected. Box 1 ### Snakebite: the scenario in South Asia #### Venomous snake speciesRETURN TO TEXT
Automated Early Detection of Myelodysplastic Syndrome with Beckman-Coulter DxH 800 Hematologyanalyzer By Using Ten Research Parameters
Authors: Noemie Ravalet, Frederic Picou, Martin Gombert, Amelie Foucault, Emmanuel Renoult, Emmanuel Gyan, Sebastien Lachot, Emmanuelle Rault, Olivier Herault
Journal: Blood (2018)
Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma
Authors: Lorenz Thurner, Sylvia Hartmann, Theresa Bock, Natalie Fadle, Maria Kemele, Evi Regitz, Moritz Bewarder, Sigrun Smola, Thorsten Pfuhl, Jana Held, Rainer-Maria Bohle, Laurence de Leval, Rabea Wagener, Reiner Siebert, Martin-Leo Hansmann, Stephan Stilgenbauer, Klaus Dieter Preuss, Michael Pfreundschuh
Journal: Blood (2018)
Abstract 19695: Burden of Acute Pericarditis on the Hospitals in USA: Analysis of Nationwide Emergency Department Sample Data
Authors: Sourabh Aggarwal, Batool Khattab, Abdel Rahman Al Emam
Journal: Circulation (2016)

Introduction: Despite a high frequency of pericardial diseases, epidemiological studies related to pericarditis are limited. This study was done to analyze the trend of burden imposed by acute peri...
Micro-Diversity: Successful Strategies and Challenges of Microbiome Sample Collection from African American and Caucasian Children with Food Allergies
Authors: Perry A. Catlin, Amal H. Assa'ad, Aame B. Andy-Nweye, Susan R. Fox, Mahboobeh Mahdavinia, Mary C. Tobin, Iman A. Abdikarim, Hemant P. Sharma, Jamie L. Fierstein, Jialing Jiang, Pamela J. Newmark, Crystal J. Johnson, Lucy A. Bilaver, Alexandria Bozen, Avneet S. Chadha, Jacqueline A. Pongracic, Ruchi S. Gupta
Journal: Journal of Allergy and Clinical Immunology (2019)
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study
Authors: Anabel Sanchez-Spitman, Vincent Dezentjé, Jesse Swen, Dirk Jan A.R. Moes, Stefan Böhringer, Erdogan Batman, Edith van Druten, Carolien Smorenburg, Aart van Bochove, Anneke Zeillemaker, Lynn Jongen, Maartje Los, Patrick Neven, Hans Gelderblom, Henk-Jan Guchelaar
Journal: Journal of Clinical Oncology (2019)

PURPOSE Tamoxifen is widely prescribed as adjuvant therapy in patients with early-stage breast cancer. It has been postulated that concentrations of endoxifen, the active metabolite of tamoxifen, are a better predictor of tamoxifen efficacy than CYP2D6 genotypes. Although in a retrospective study, an endoxifen threshold of 5.9 ng/mL for efficacy was described, confirmation based on prospective studies is lacking. The objective of the prospective CYPTAM (The Netherlands National Trial Register: NTR1509) study was to associate endoxifen concentrations and CYP2D6 genotypes with clinical outcome in patients with early-stage breast cancer receiving tamoxifen. PATIENTS AND METHODS From February 2008 to December 2010, patients with breast cancer treated with adjuvant tamoxifen were included. Patients could be enrolled up to a maximum of 12 months after tamoxifen initiation. Blood samples were retrieved for CYP2D6 genotyping and endoxifen measurements by Amplichip (Roche Diagnostics, Indianapolis, IN) and high-performance liquid chromatography–tandem mass spectrometry, respectively. Endoxifen concentrations were analyzed as a continuous variable, classifying patients into quartiles and using an endoxifen threshold of 5.9 ng/mL. Endoxifen concentrations and CYP2D6 genotypes were associated with relapse-free survival (censored at the time of tamoxifen discontinuation; RFSt) by Cox regression analysis. RESULTS A total of 667 pre- and postmenopausal patients were enrolled and had received tamoxifen for a median time of 0.37 years (range, 0.23 to 0.6 years) before study entry. No association was found between endoxifen concentrations and RFSt (adjusted hazard ratio, 0.991; 95% CI, 0.946 to 1.038; P = .691). Also, neither categorizing endoxifen concentrations into quartiles nor using 5.9 ng/mL as threshold altered these results. In addition, no association was found between CYP2D6 genotype and RFSt (adjusted hazard ratio, 0.929; 95% CI, 0.525 to 1.642; P = .799). CONCLUSION This prospective clinical study shows no association between endoxifen concentrations or CYP2D6 genotypes and clinical outcome in patients with early-stage breast cancer receiving adjuvant tamoxifen.
White matter has impaired resting oxygen delivery in sickle cell patients
Authors: Yaqiong Chai, Adam M. Bush, Julie Coloigner, Aart J. Nederveen, Benita Tamrazi, Chau Vu, Soyoung Choi, Thomas D. Coates, Natasha Lepore, John C. Wood
Journal: American Journal of Hematology (2019)

Although modern medical management has lowered overt stroke occurrence in patients with sickle cell disease (SCD), progressive white matter (WM) damage remains common. It is known that cerebral blood flow (CBF) increases to compensate for anemia, but sufficiency of cerebral oxygen delivery, especially in the WM, has not been systematically investigated. Cerebral perfusion was measured by arterial spin labeling in 32 SCD patients (age range: 10‐42 years old, 14 males, 7 with HbSC, 25 HbSS) and 25 age and race‐matched healthy controls (age range: 15‐45 years old, 10 males, 12 with HbAS, 13 HbAA); 8/24 SCD patients were receiving regular blood transfusions and 14/24 non‐transfused SCD patients were taking hydroxyurea. Imaging data from control subjects were used to calculate maps for CBF and oxygen delivery in SCD patients and their T‐score maps. Whole brain CBF was increased in SCD patients with a mean T‐score of 0.5 and correlated with lactate dehydrogenase (r 2 = 0.58, P &lt; 0.0001). When corrected for oxygen content and arterial saturation, whole brain and gray matter (GM) oxygen delivery were normal in SCD, but WM oxygen delivery was 35% lower than in controls. Age and hematocrit were the strongest predictors for WM CBF and oxygen delivery in patients with SCD. There was spatial co‐localization between regions of low oxygen delivery and WM hyperintensities on T2 FLAIR imaging. To conclude, oxygen delivery is preserved in the GM of SCD patients, but is decreased throughout the WM, particularly in areas prone to WM silent strokes.
Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications
Authors: Giuseppe Gaipa, Chiara Francesca Magnani, Daniela Belotti, Giada Matera, Sarah Tettamanti, Benedetta Cabiati, Stefania Cesana, Valentina Colombo, Giovanni Cazzaniga, Grazia Fazio, Chiara Buracchi, Silvia Rigamonti, Attilio Rovelli, Adriana Balduzzi, Sara Napolitano, Eugenio Montini, Gian Maria Borleri, Giuseppe Gritti, Federico Lussana, Martino Introna, Alessandro Rambaldi, Giuseppe Dastoli, Andrea Biondi
Journal: Blood (2018)
Abstract 18932: Safety and Efficacy of New- vs. Early-Generation Drug-Eluting Stents in Elderly Women: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration
Authors: Birgit Vogel, Usman Baber, Gennaro Giustino, Samantha Sartori, Martin Leon, Giulio Stefanini, William Wijns, P. Gabriel Steg, Marie-Claude Morice, Giora Weisz, Clemens Von Birgelen, George Dangas, Jaya Chandrasekhar, Serdar Farhan, Sabato Sorrentino, Clayton Snyder, Soren Galatius, Hyo-Soo Kim, Dipti Itchhaporia, Laxmi Mehta, Alaide Chieffo, Roxana Mehran
Journal: Circulation (2017)

Introduction: Data on new- vs. early-generation (gen) drug-eluting stents (DES) in elderly female patients undergoing percutaneous coronary intervention (PCI) are limited. Objective: To investigate clinical outcomes associated with new- vs. early gen DES in elderly female patients undergoing PCI. Methods: We pooled patient-level data from 26 randomized controlled trials. Female patients ≥70 years of age were included in this analysis. Device-oriented endpoints (EP) included stent thrombosis (ST) and target lesion revascularization (TLR), whereas patient-oriented EP included myocardial infarction (MI) and death. 3-year outcomes were assessed using Cox regression modeling with trial entered as a random effect. Results: Of 4,631 female patients ≥70 years of age, 2,721 (58.76%) received exclusively new-gen DES. Compared with early-gen DES, the use of new-gen DES resulted in lower TLR rates (5.1% vs. 6.7%, p=0.023) and a strong trend towards lower ST rates (0.6% vs. 1.2%; p=0.055). However, MI and death rates ...
Racial/Ethnic Disparities in Neonatal Outcomes
Authors: Olga Basso
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 17197: Prevalence and Severity of Malnutrition in Children With End-Stage Heart Failure Evaluated for Heart Transplantation
Authors: Katelin M Dennis, Kelsey A Christenson, Lisa M Schultz, Alaina K Kipps, Marcy Snyder, John C Dykes, Katsuhide Maeda, Beth D Kaufman, Seth A Hollander, Kristin Jensen, Shannon Feehan, David N Rosenthal, Christopher S Almond
Journal: Circulation (2016)

Background: Malnutrition is an important complication of end-stage heart failure (HF) in children. The prevalence and severity of malnutrition in pediatric advanced HF patients is unknown. We sough...